Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Recurium Equity, LLC — Zentalis Pharmaceuticals, Inc. insider: 1 transactions · InsiderLens

Home / Insiders / Recurium Equity, LLC

Recurium Equity, LLC

10% owner at Zentalis Pharmaceuticals, Inc. · on record since Apr 3, 2020

Insider trading activity of Recurium Equity, LLC

Transactions on record: 1; since Oct 30, 2020

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Oct 30, 2020

Figures computed from official regulatory filings — methodology.

Companies where Recurium Equity, LLC has traded

Zentalis Pharmaceuticals, Inc.1 tx · Oct 30, 2020

Track record of Recurium Equity, LLC

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Recurium Equity, LLC

Co-insiders of Recurium Equity, LLC

Blackwell KimberlyZentalis Pharmaceuticals, Inc.
Brownstein CarrieZentalis Pharmaceuticals, Inc.
Bruns IngmarZentalis Pharmaceuticals, Inc.
Bucher James BZentalis Pharmaceuticals, Inc.
Bunker Kevin D.Zentalis Pharmaceuticals, Inc.
Campbell ShannonZentalis Pharmaceuticals, Inc.
EASTLAND JULIA MARIEZentalis Pharmaceuticals, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Epperly Melissa B,Zentalis Pharmaceuticals, Inc.

Gallagher CamZentalis Pharmaceuticals, Inc.

GOEL DAVID E.Zentalis Pharmaceuticals, Inc.

HALVORSEN OLE ANDREASZentalis Pharmaceuticals, Inc.

HAUSMAN DIANAZentalis Pharmaceuticals, Inc.

Johnson David MichaelZentalis Pharmaceuticals, Inc.

Kariuki EnochZentalis Pharmaceuticals, Inc.

Lackner MarkZentalis Pharmaceuticals, Inc.

Matrix Capital Management Company, LPZentalis Pharmaceuticals, Inc.

Myers Scott DunsethZentalis Pharmaceuticals, Inc.

Ott David C.Zentalis Pharmaceuticals, Inc.

Paul AndreaZentalis Pharmaceuticals, Inc.

Pinto AlexisZentalis Pharmaceuticals, Inc.

Roth IrisZentalis Pharmaceuticals, Inc.

Shabet Rose SharonZentalis Pharmaceuticals, Inc.

Skvarka JanZentalis Pharmaceuticals, Inc.

SUN ANTHONY YZentalis Pharmaceuticals, Inc.

Takhar Karan S.Zentalis Pharmaceuticals, Inc.

VIKING GLOBAL INVESTORS LPZentalis Pharmaceuticals, Inc.

Viking Global Opportunities GP LLCZentalis Pharmaceuticals, Inc.

Viking Global Opportunities Illiquid Investments Sub-Master LPZentalis Pharmaceuticals, Inc.

Viking Global Opportunities Portfolio GP LLCZentalis Pharmaceuticals, Inc.

Voliotis DimitrisZentalis Pharmaceuticals, Inc.

Vultaggio VincentZentalis Pharmaceuticals, Inc.

Walker Luke NathanielZentalis Pharmaceuticals, Inc.

WALTERS GROUPZentalis Pharmaceuticals, Inc.

WALTERS SUSAN BERKLEYZentalis Pharmaceuticals, Inc.

WALTERS WILLIAM THURMANZentalis Pharmaceuticals, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Zentalis Pharmaceuticals, Inc.	Oct 30, 2020	Other	-4,147,940	0.00 USD	$0	SEC